Diagnostic Imaging in the Staging of Prostate Cancer

This document was published more than 2 years ago. The nature of the evidence may have changed.

Conclusions

This report assesses different diagnostic imaging techniques (magnetic resonance tomography, positron emission tomography, and positron emission tomography with computed tomography to assess local tumour extent, i.e. whether it is limited to the prostate gland itself, or if it has grown outside the prostate gland (T stage), or spread to the nearby lymph nodes (N stage).

  • Overall: Staging is important in the choice of treatment strategy. There is no scientific evidence for the benefits of the diagnostic imaging techniques. There is no support for using resources for the routine use of these techniques without following them up scientifically. Systematically documented experience gained through use of these techniques contribute to their continuous development.
  • Use and benefits: Diagnostic imaging is used at many medical facilities in Sweden in order to stage prostate cancer (T and N categories). However, it is not currently possible to assess whether this leads to an increased survival rate or better quality of life since there are no relevant studies.
  • Performance of the techniques: It is not possible to determine how reliable the techniques are for the correct staging of prostate cancer. The limited evidence available shows that examinations using positron tomography with simultaneous CT scan using one of the trace elements (11C choline) provides a relatively high to high specificity (84–98%), while the technique’s sensitivity is lower and more uncertain (45–84%) for the assessment of the N stage for persons with inter­mediate and high risk tumours.
  • Potential risks: As the reliability of these techniques is still uncertain, it is possible that their use will lead physicians to make misguided decisions that could adversely affect patient health. It is therefore important that the person interpreting the images and the treating doctor are aware that the reliability of these diagnostic techniques has not been determined. Patients examined with these techniques must also be informed about these reliability issues.
  • Economic aspects: The cost of one examination using MRT is approximately SEK 6,500 and PET/CT around SEK 17,000. It is not currently possible to assess whether it is cost-effective to use these diagnostic imaging techniques because their reliability and effects on patient health are still unclear. Since prostate cancer is a common disease, and resources are limited, the increased use of diagnostic imaging in staging prostate cancer could displace other patient groups, putting them at a disadvantage.
  • Continued research: In order to address how patient health is affected, randomized studies of the various diagnostic techniques are required in which survival rates, symptoms and quality of life are followed up for a very long time after treatment. In order to assess the diagnostic accuracy of the imaging techniques, more high quality studies are required that follow patients forward in time (prospective). Several reviewers must also make assessments independently of each other and of other information (blinding). In future research, all parts of the studies – trial subjects, diagnostic techniques and comparisons – must be better described.

How to cite this report: SBU. Diagnostic imaging in the staging of prostate cancer. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2014. SBU report no 2014-04 (in Swedish).

Download summary

SBU Assessment presents a comprehensive, systematic assessment of available scientific evidence. The certainty of the evidence for each finding is systematically reviewed and graded. Full assessments include economic, social, and ethical impact analyses.

SBU assessments are performed by a team of leading professional practitioners and academics, patient/user representatives and SBU staff. Prior to approval and publication, assessments are reviewed by independent experts, SBU’s Scientific Advisory Committees and Board of Directors.

Published: 9/9/2014
Contact SBU: registrator@sbu.se
Report no: 2014-04
http://www.sbu.se/201404e

Project group

Experts

  • Ove Andrén, Associate Professor, Chief Physician, Örebro University Hospital (Chair)
  • Lennart Blomqvist, Professor, Chief Physician, Örebro University Hospital
  • Stefan Carlsson, PhD, Chief Physician, Karolinska University Hospital
  • Peter Gjertsson, Associate Professor, Chief Physician, Sahlgrenska University Hospital

SBU

  • Monica Hultcrantz, Project Manager
  • Agneta Pettersson, Assistant Project Manager
  • Emelie Heintz, Health Economist
  • Agneta Brolund, Information Specialist
  • Anna Attergren Granath, Project Administrator

Scientific reviewers

  • Håkan Ahlström, Professor, Chief Physician, Akademiska sjukhuset, Uppsala
  • Olof Akre, Assosiate Professor, Karolinska Institutet, Stockholm
  • Ingela Franck Lissbrant, PhD, Sahlgrenska akademin at Göteborgs University
  • Jens Sörensen, Professor, Chief Physician, Akademiska sjukhuset, Uppsala